Thursday, April 2, 2026 | 5:30 – 7:00 PM EST
Black and Blue Steak and Crab
1470 Western Avenue, Albany, NY 12203
MedHive: Collective Clinical Knowledge Advancing Patient Care
Earn up to 1.0 AMA and/or ABIM MOC credit/point
Join us April 2nd, from 5:30-7:30 PM EST for a free CME dinner event
and be part of an interactive, community-focused discussion on real-world experiences and challenges in managing Type 2 Diabetes.
This MedHive™ educational initiative focuses on empowering endocrinologists to deliver personalized, evidence-based care for patients with Type 2 Diabetes. Through interactive peer discussions and expert insights, participants will contribute their collective knowledge to explore strategies to optimize therapy selection, improve adherence, and achieve both glycemic and extra-glycemic goals aligned with the latest 2025 ADA Standards of Care.
Meet Our Faculty
Marc-Andre Cornier, MD, FTOS, FAHA
James A. Keating Endowed Chair in Diabetes
Director, Division of Endocrinology, Diabetes & Metabolic Diseases
Medical University of South Carolina
Charleston, SC
In-Person Registration
In-Person Attendees Must Be Registered for IASLC 2025
To attend in person, you must be registered as an IASLC attendee. If you can’t join onsite, this session is also available FREE via livestream on our social channels or Zoom. Virtual participants can still earn credit, but will need to register below to receive instructions for claiming credit.
Endocrinologists involved in the care of patients with type 2 diabetes (T2D) in the United States
- Managing T2D: There Is a Lot to Consider
- Ongoing Management: Assessing Adherence and Efficacy
- When Patients Are Adherent but Not at Goal
- Key Strategies/Wrap-Up
After completing this activity, the participant should be better able to:
Develop personalized management plans for patients with type 2 diabetes (T2D) based on current guidelines, the most recent evidence, patients’ comorbidities, and shared decision-making with an educated patient
Assess glycemic and extra-glycemic control on a regular basis including evaluating patient adherence to their current regimen and medication efficacy
Intensify antihyperglycemic therapy as needed incorporating new data, new treatments, and guideline modifications.
This activity is provided by MLI
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
Support Statement
This activity is supported by an educational grant from Lilly.
Medical Learning Institute Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.
To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education.
All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Planner/Presenter
Marc-André Cornier, MD, FTOS, FAHA has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: AstraZeneca, Biophytis, Bonus Health, Enveda, Keros, Lilly, Novo Nordisk, Rivus, Wave, ZyVersa
Research Funding/Support (to institution): Cleery, Ionis, Kaneka, Novartis
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management.
Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity, however, registration is required. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
About This Activity
Medical Learning Institute Inc is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.
Copyright © 2025 Medical Learning Institute Inc. All Rights Reserved.
This activity is supported by an educational grant from Lilly.